Investigational drug · Phase 3
SCTB35
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for NHL - Non-Hodgkin's Lymphoma, Follicular Lymphoma (FL), System Lupus Erythematosus.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
5
Any phase or sponsor naming "SCTB35"
First trial start
2025
Feb 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SCTB35", any sponsor or status.
Conditions studied
As listed on its trial records.
- NHL - Non-Hodgkin's Lymphoma
- Follicular Lymphoma (FL)
- System Lupus Erythematosus
- DLBCL - Diffuse Large B Cell Lymphoma
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "SCTB35" as an intervention, largest first.
Sinocelltech Ltd.Industry
NCT06841042 · 168 participants (planned) · Start Feb 2025 · Primary completion May 2027
Drug: SCTB35 injection · For: System Lupus Erythematosus
Sites: Beijing, China; Changchun, China; Guangzhou, China · 14 sites in all
- A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaPivotal-lookingRecruiting
Sinocelltech Ltd.Industry
NCT07570823 · 101 participants (planned) · Start Jun 4, 2026 · Primary completion Nov 2027
Drug: SCTB35 injection; Rituxumab and 2 more · For: DLBCL - Diffuse Large B Cell Lymphoma
Sites: Beijing, China
- A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular LymphomaPivotal-lookingRecruiting
Sinocelltech Ltd.Industry
NCT07562022 · 93 participants (planned) · Start Jun 9, 2026 · Primary completion May 2028
Drug: SCTB35 injection; Rituximab and 1 more · For: Follicular Lymphoma (FL)
Sites: Beijing, China
- SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin LymphomaNot yet recruiting
Sinocelltech Ltd.Industry
NCT07819188 · 90 participants (planned) · Start Sep 30, 2026 · Primary completion Sep 30, 2028
Drug: SCTB35 injection; SCTB41 · For: NHL - Non-Hodgkin's Lymphoma
Sites: Tianjing, China
- A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin LymphomaNot yet recruiting
Sinocelltech Ltd.Industry
NCT06318884 · 76 participants (planned) · Start Apr 2024 · Primary completion Oct 2026
Drug: SCTB35 injection · For: Non-Hodgkin Lymphoma, B-cell
Sites: Beijing, China; Zhengzhou, China; Tianjin, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for NHL - Non-Hodgkin's Lymphoma
- SCTB41Phase 36 trials
Sinocelltech Ltd. · NHL - Non-Hodgkin's Lymphoma, NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Malignant Solid Tumor
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.